York Pharma Share Discussion Threads

[risk1] 31/1/2009 16:27

I never listen to that twerp bioshark

most of the fall in share price can be attributed to general market turmoil especially with aim stocks which I personally see as a buying opportunity

Abasol has not been rejected nor is it likely to be imho (they would have done it by now if that was the case)

all imo dyor

Nobby please help that idiots back

[nigelbunting] 31/1/2009 16:18

Risk
Out of interest - Why?

[risk1] 31/1/2009 16:07

well i for one will be topping up on Monday

what a bargain we have here

[bioshark] 28/1/2009 16:41

poor Nobby ;-) you should have listened to the facts I gave to you over the years on abasol and TS.

well, some just have to learn the hard way

[handycam] 23/1/2009 22:22

"Mr. Anderson. You are the chosen one."

Give the man a chance. Anyone who loses £1m taking YRK paper for his Crawford Healthcare will be more motivated above anything else.

[jpendle] 23/1/2009 17:59

Knowing how incompetent the management are, it wouldn't surprise me to find they forgot to put a stamp on the application envelope and it never arrived - I bet they've never though to ask how its progressing.

I bought this share because I thought the pharmas were protected from the credit crunch - good ones are doing well but not those run by idiots.

Imagine extnding the life of Warrants a few weeks ago - they should have made then exercisable immediately only at a sensible price - p*llocks

Sorry for rambling on, I think the answer to your question is No. It must be company confidential and I think YRK wouldn't tell you anything, it would be RNS stuff, and would you believe them anyway.

[bjfanc] 22/1/2009 16:36

Is there a way to find out whether or not more information was asked for on Abasol ?
i.e. will the MHRA give out any details. As I cannot believe that there has be no correspondence over the past however many years.

[nobbygnome] 21/1/2009 18:37

>>roorontev (just worked out you are a fellow United supporter. Correct?)

Very clever but I think that is called plagarism............;0)

At the risk of being called a ramper...........I really do think some of you guys can't see the wood for the trees.

I think pronouncing the death of YRK is a little premature. Unlike most biotech companies, despite the recent debacle they still have products which are selling. I am sure that breakeven will now be delayed but I am also sure that the new management will cut a lot of projects, sack a few people and reach breakeven more quickly.

Also you seem to forget that this really is now all about Abasol (if it wsn't before). Until we hear otherwise we have to assume this will be approved...........eventually! The current market cap is less than £4 million. I am sure Abasol won't be a particularly great selling drug but sure as night follows day, it is worth considerably more than £4 million!

So clearly recent events are a major setback but do not throw the baby out with the bath water and get some perspective!

Regards to all

Nobby (preparing for flak......)

[wetdream] 20/1/2009 19:41

Re-arranging deckchairs on the Titanic.

[nigelbunting] 20/1/2009 17:00

Board Changes & Market Update

www.investegate.co.uk/article.aspx?id=200901201419359449L&fe=1

[bignads] 20/1/2009 13:41

Interesting to note in the context of reneuron, that it got the go-ahead from MHRA to proceed with stem-cell research within one year. Yet it has taken MHRA almost twice that long to return a decision on a topical skin-cream, abasol. Where is the risk assessment there?!

[wetdream] 16/1/2009 14:28

Possibly the same one who dealt with Bioglan!
How ironic!

[jpendle] 16/1/2009 09:55

This also may cause the sales collaboration with sinclair to collapse now we can't offer the sales that were presumably promised?

What a mess, of the boards own making - expanding during a credit squeeze and borrowing from a dubious source.

But the worst thing is that they were so nieve as to try to do a deal behind the back of the new investor - see RNS.

If we didn't have the money to complete the deal we shouldn't have gone forward - director ego surfacing again I suppose.

Thought of averaging down but resisted the temptation as I suspect this may be one for the administrator.

[bignads] 16/1/2009 08:31

Roorontev

I'm not excusing them of any blame - just saying that they could legitimately point to some mitigating factors. They still screwed up big time mind you!

[roorontev] 16/1/2009 08:19

"Abasol application for so long. Damn bureaucrats!"

With no blame being aimed at the YRK board then?.....Or chief ramper Nobby...ROTFLMAO....;-))

[bignads] 16/1/2009 08:14

Yeah, the fortress withdrawal sounded like a fund desperately trying to claw back money from wherever it could. In the end, I think York has been unlucky with the timing of this deal, and in some ways I'm surprised they managed to get it through as far as they did. Chances are slim of finding another buyer in this economic climate, but you never know. Most of the blame probably lies with the UK regulatory authorities for sitting on the Abasol application for so long. Damn bureaucrats!

[wetdream] 15/1/2009 20:57

The Vulture's got eaten!
;-)

[handycam] 15/1/2009 19:58

Like other alternative-investment firms, Fortress faces incredible difficulty raising new capital as asset values have declined, returns have become more meager and investors are clinging to cash for dear life. A tidal wave of redemptions from existing clients forced Fortress to halt further investor withdrawals from its Drawbridge Global Macro Fund in December, about a month after the firm posted a third-quarter loss that fell far below Wall Street's profit expectation.

Fortress' liquid hedge-fund segment -- which includes Drawbridge Global Macro and Fortress Commodities Funds -- accounts for $9.1 billion worth of capital, and clients can ask for their money back at the end of every quarter. The most recent available figures show that clients demanded $5.6 billion of their cash back in 2008.

Fortress' other hedge-fund business -- a hybrid one that includes Drawbridge Special Opportunities Funds and Fortress Partners Funds -- accounted for $8.2 billion worth of capital. Although those funds have more strings attached to redemptions, clients still asked to withdraw $2.3 billion last year.

Jeffries & Co. analyst Daniel T. Fannon estimates that when all is said and done, assets under management in Fortress' hedge-fund group will fall by nearly 40% to $10.5 billion. As the hedge-fund world navigates through dire straits, Fortress' other business -- private-equity -- didn't lose any capital, but also has the luxury of long-term restrictions around its funds.



No wonder they asked for their money back.

[wetdream] 15/1/2009 17:51

Seems like Fortress could be heading the same way as YRK!

[wetdream] 15/1/2009 10:59

Since the company's mkt cap is only £4m, guess someone may be prepared to make an offer for the remains.
should make the results mtg in a week's time very tense.

[roorontev] 15/1/2009 09:58

roorontev - 4 Dec'08 - 16:26 - 2524 of 2595 edit


Same here......

The chance of licensng a programme wih your back against the wall........virtually zero. Big pharma can wait until they are nearly bankrupt (or completely bankrupt) and pick up the targets on the cheap. They will be in no hurry to sign anything.

The best deal for shareholders would be to turn out the lights now and return the small amount of cash to the shareholders. Very sad but I fear the old problem that scientists make poor mangers has struck again!

[wetdream] 15/1/2009 09:12

Absolutely right.
No lessons learned, I'm afraid.
RIP

[jpendle] 15/1/2009 07:37

Didn't some institutions put in extra money to help the expansion.

They may well now look for some sort of compensation, if they have a legal case for mis-selling.

I hope the company can pull a rabbit out of a hat or some other trick to survive, but I think this is a repeat of Boiglen as suggested above.

'A man with a big Ego that doesn't know when to stop digging'

[topvest] 14/1/2009 21:36

Disaster looming I'm afraid - when Sadler announces this bungled acquisition and a strategic review...with no positives...you know it's bad. Accounts haven't been released either, so going concern issues also v.likely. Have they spent any cash on this acqusition which is non-refundable/acquired a part debt facility? Sounds like it may be the end i'm afraid. Didn't Terry say he wouldn't make the same mistake as Bioglan and finance deals with debt...he has! A sad story.
......Anyone remember Abasol? That was York Pharma!!!

[jpendle] 14/1/2009 17:21

I doubt that Fortress have just walked away - now the two companies are well and truely distressed they may stick around to see if they can pick up the pieces for a pittence - if they a true vulture capitalists they'll aways look for and angle to extract more money.

Its probable that they would only put money up on the basis of some other capital injection to reduce their risk - however IMO we are unlikely to learn the truth fron YRK management.

Sadler does halt spin a good yarn, where the drug approval we were expecting?